What question did this study set out to answer?

The study aims to evaluate treatment patterns and vial usage of elranatamab in patients with multiple myeloma in Japan.

March 14, 2026ClinicoEconomics and Outcomes ResearchOpen Access

Real-World Treatment Patterns of Elranatamab in Patients with Multiple Myeloma in Japan: The EVEREST Study

View Full Paper

Ask AI

Bookmark

The study aims to evaluate treatment patterns and vial usage of elranatamab in patients with multiple myeloma in Japan.
Retrospective analysis using de-identified claims data from the MDV database.
Included adults with multiple myeloma who started elranatamab treatment.
Follow-up divided into step-up dosing and two maintenance periods; descriptive reporting of treatment patterns.
253 patients with a median age of 74 years included.
Median treatment duration was 60.0 days.
Annual elranatamab usage was 34.4 vials, lower than the recommended 39.0 vials per year.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective study evaluates elranatamab treatment patterns in multiple myeloma patients, suggesting variable dosing occurs in the real-world setting.

Cite This Study

Yoshihara et al. (2026) studied this question.

synapsesocial.com/papers/69b4faf0b39f7826a300b9ea https://doi.org/10.2147/ceor.s581258

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study evaluates elranatamab treatment patterns in multiple myeloma patients, suggesting variable dosing occurs in the real-world setting.

Real-World Treatment Patterns of Elranatamab in Patients with Multiple Myeloma in Japan: The EVEREST Study

Key Points

Discussion

Implication

Cite This Study

Real-World Treatment Patterns of Elranatamab in Patients with Multiple Myeloma in Japan: The EVEREST Study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider